"The study findings provide new information on the risk of hospitalisation for heart failure for DPP-4 inhibitors and specifically for saxagliptin relative to sitagliptin within this class," said lead investigator Alex Fu of Georgetown University Medical Center in the US
Reading the writing on the wall and what it may signify, telemarketing companies, pharmacies, and other stakeholders selling GLP-1 products that are not FDA approved should consider this change in tone and action from both FDA and manufacturers in planning for the future, including in preparing to defend ongoing GLP-1 compounding or potentially realigning their compounding capacity for future markets
We are pleased the FDA has declared that supply of the only real, FDA-approved semaglutide medicines is resolved, affirming that Novo Nordisk is meeting or exceeding current and projected nationwide demand, said Dave Moore, executive vice president of U.S
Guo X, Cheng Y, Zhao X, Luo Y, Chen J, Yuan WE